Amgen's EBIT per Share for the
three
months ended in Dec. 2023 was $3.11.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $19.95.
During the past 12 months, the average EBIT per Share Growth Rate of Amgen was -17.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -1.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 0.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 7.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Amgen's EBIT per Share or its related term are showing as below:
AMGN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -81.7 Med: 14.45 Max: 139.6
Current: -1.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Amgen was 139.60% per year. The lowest was -81.70% per year. And the median was 14.45% per year.
AMGN's 3-Year EBIT Growth Rate is ranked worse than 65.26% of 852
companies
in the Drug Manufacturers industry
Industry Median: 8.05
vs AMGN: -1.80
Amgen's EBIT for the
three
months ended in Dec. 2023 was $1,673 Mil.
Amgen EBIT per Share Historical Data
The historical data trend for Amgen's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (NAS:AMGN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Amgen EBIT per Share Related Terms
Thank you for viewing the detailed overview of Amgen's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMGN has been successfully added to your 